Global Viral Vector Manufacturing Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

DUBLIN, March 4, 2022 /PRNewswire/ -- The "Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global viral vector manufacturing market reached a value of US$ 746.6 Million in 2021. Looking forward, the publisher expects the market to reach a value of US$ 3,162.5 Million by 2027 exhibiting a CAGR of 25.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs).

Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, disease, application and end user.

Breakup by Type:

• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others

Breakup by Disease:

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Breakup by Application:

• Gene Therapy
• Vaccinology

Breakup by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Key Questions Answered in this Report:

• How has the global viral vector manufacturing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global viral vector manufacturing market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the disease?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global viral vector manufacturing market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Viral Vector Manufacturing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type
6.1 Adenoviral Vectors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Adeno-associated Viral Vectors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Lentiviral Vectors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Retroviral Vectors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast

7 Market Breakup by Disease
7.1 Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Genetic Disorders
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Infectious Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast

8 Market Breakup by Application
8.1 Gene Therapy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Vaccinology
8.2.1 Market Trends
8.2.2 Market Forecast

9 Market Breakup by End User
9.1 Pharmaceutical and Biopharmaceutical Companies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Research Institutes
9.2.1 Market Trends
9.2.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Cognate BioServices Inc. (Charles River Laboratories International Inc.)
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 F. Hoffmann-La Roche AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.3 FinVector Oy
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 FUJIFILM Holdings Corporation
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Kaneka Eurogentec S.A. (Kaneka Corporation)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Lonza Group AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Oxford Biomedica plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 REGENXBIO Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanofi S.A.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Thermo Fisher Scientific Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 uniQure N.V.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials

For more information about this report visit https://www.researchandmarkets.com/r/sd9eh3

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets